2025 SPEAKERS
Omar Ali, Visiting Lecturer, VBA & Former Advisor, NICE, University of Portsmouth
Herbert Altmann, Head of Market Access, Pricing and Reimbursement Europe, Cencora Pharmalex
Samia Aly, Executive Director, Value & Access, Innovative Medicines Europe, Novartis
Luigi Angelillo, Director, Market Access EMEA, Argenx
Ad Antonisse, Director, Market Access & External Affairs, Astrazeneca
Jose Aragunde, Value and Pricing Strategy Lead, Market Access, Novartis
Diego Ardigò, Research & Development Head & Executive Board Member and Vice Chair, Chiesi Group & EUCOPE
Jorge Arellano, Vice President, Head of Intercontinental Markets, Market Access, Pricing, & Value Demonstration, Bristol Myers Squibb
Marnix Artz, Head Patient Access, Pricing & Governmental Affairs, Merck Group
Nico Bacharidis, Chief Commercial Officer, Cube RM
Andrew Ballantyne, Vice President, Ipsos Market Access
Johnny Bane, Head of Market Access, Accord Healthcare
Sylvaine Barbier, Principal, RWE & Biostatistics, Putnam
Alexander Bastian, Advisor, Market Access, A.M. Pharma & Memo Therapeutics
Dianne Baunbaek, Precision Medicine Lead, Janssen Pharmaceutical
Ahmad Bechara, Executive Vice President, Pharma, Alira Health
Tomer Ben Zaken, Head of Commercial Operations & Trade, Astellas
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, Astrazeneca
Rito Bergemann, Vice President, Health Economics and Outcomes Research, Parexel
Nick Besseling, Manager, Value Strategies & Agreements, Astrazeneca
Ingrid Bettum, Senior Advisor, Norwegian Medicines Agency
Chris Bidad, Global Head, Access Strategy and Payer Policy, Astrazeneca
Matthias Bischof, Senior Director, Global Health Economics, Novartis Gene Therapies
Jesper Bjerggren, Associate Director, European Market Access, Teva Pharmaceuticals
Marie-Sharmila Blandino, Director, Global Access Strategy Lead, Amgen
Alice Blezat, Global Value-Based Contracting & Health Outcomes Solution Lead, EY
Par Bolina, Adjunct Associate Professor, Medicinal Chemistry, Rutgers university
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Anh Bourcet (Nguyen), Strategic Advisor, Market Access Leader, APACMed, Asia Pacific Medical Technology Association
Vidya Breeveld, Independent Market Access Expert
Jennifer Bright, President, ICHOM
Alberto Briones, Engagement Manager, Lifescience Dynamics
Sangeeta Budhia, Vice President, Pricing & Market Access, Parexel
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Hatice Camdere, Executive Director, Value, Access & Policy, Amgen
Gorana Capkun, Vice President, Global Head of Patient Focused Real World Evidence, Merck Group
Lorenzo Capretto, Market Access Lead EU&EM, Global Rare Disease, Chiesi Farmaceutici SpA
Ivo Carre, Business Analyst, Lifescience Dynamics Ltd
Sandro Cesaro, Head of Europe Market Access & Pricing, Astrazeneca
François-Xavier Chalet, Associate Director, Health Economics Expert, Idorsia Pharmaceutical Ltd.
Catherine Chamoux, Principal, AESARA
Abbey Child, Senior Consultant, Cogentia
José Luis Sánchez Chorro, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Paolo Correale, Senior Principal, Global Pricing & Access Consulting, Eversana
Paolo Angelo Cortesi, Assistant Professor in Public Health, Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
Elisa Crovato, Director, Pricing & Market Access, Chiesi Group
Alan Crowther, General Manager, Global Pricing & Access, Eversana
Marcus Dahlman, Head of Market Access Europe, Hansa Biopharma
Nidhi Dani, Director, Global Market Access, Novartis
Adrien De Montgolfier, Global Pricing Analyst, FERRING
Emanuele Degortes, Vice President, Global Head of Access Policy and Patient Advocacy, Menarini
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Eva Susanne Dietrich, Professor for Pharmacoeconomics and HTA, University of Bonn
Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
Riad Dirani, Vice President, Global HEOR, Medical Operations & Excellence, Teva Pharmaceuticals
Patricia Dorling, Head, Global HEOR and Real World Evidence, Chiesi Group
Filippo Drago, Full Professor of Clinical Pharmacology, University of Catania
Ahmed Edathodu, Founding Director, Access Infinity Ltd
Ruven Remo Eul, Principal, Life Sciences, Marbls
Joanne Evason, Partner, Putnam
Gina Ewy, VP, Head of Global Market Access, Hansa Biopharma
Marina Faiella, Head, Forecasting and Business Analytics, Europe, BeiGene
Peter Fassler, Director, Market Access, Gilead Sciences
Diar Fattah, Director, Health Economics and Outcomes Research, Vertex Pharmaceuticals
Girisha Fernando, Chief Executive Officer, Lyfegen
Sarah Ferry, Senior Policy Advisor, Innovation & Life Sciences, NHS Confederation
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Graham Foxon, Managing Director, Remap Consulting
Neil Gallagher, Managing Economist, Copenhagen Economics
Benjamin Gannon, Vice President, International, Guardant Health
Martina Garau, Director, Office of Health Economics
Sonia García Pérez, HTACG representative. Head of international affairs., AEMPS
Suzanne Gaunt, Chief Executive Officer, Your Advisor
Alexander Gee, Senior Director, Customer Strategy, Parexel
Fabrizio Gianfrate, Full Professor, Health Economics and Outcomes Research, Former AIFA
Jonathan Gibson, Market Access Consultant, Initiate Consultancy
Ramiro Gilardino, Senior Director, Global HTA & Access Policy Lead, MSD
Thomas Gilboy, Product Owner, Access Infinity
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson
Tristan Gloede, Executive Director, Global Head of Market Access Retinal Health, Boehringer Ingelheim
Josie Godfrey, Co-Chief Executive Officer, Realise Advocacy
Niovi Gounopoulou, Business Analyst, Lifescience Dynamics Ltd
Maja Graf, Associate Director, Policy & Market Access, Medicines for Europe
Ingolf Griebsch, Global Head, Health Economics & Outcome Research, Ferring Pharmaceuticals
Thomas Grub, Senior Expert, Global Pricing and Market Access, medac GmbH
Neil Grubert, Global Market Access Consultant, Independent
Josep Maria Guiu Segura, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Marlene Gyldmark, Head Access Evidence, Idorsia
Janice Haigh, Practice Lead, Remap Consulting
Matthew Hanchard, Research Fellow, University of Sheffield
Günter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Hugo Hayes, Manager, Putnam
Alison Horsfield, Director, Global Access Strategy, AstraZeneca
Ruth Howells, Senior Director, Head of HTA, Clarivate
Kirsty Hoyle, Chief Executive Officer, Metabolic Support UK
Tijana Ignjatovic, Executive Director, Genesis Research Group
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Dawn Ireland, President & Founder, CDH International
Khalid Ismail, Senior Manager, Market Access Benelux, CSL Behring
Shrividya Iyer, Principal, Value Pricing & Access (VPA), Putnam Associates
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Daniel Jackson, Global Head, Market Access Policy, Ucb
Swiderski Jan, Public Affairs Director, IPSEN PHARMA S.A.
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Rosemary Jose, Executive Director, Market Access & HEOR, OPEN Health
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Lisette Kaskens, Director, Market Access, Europe, LATAM & Canada, Ferring Pharmaceuticals
Sebastian Kessel, Senior Director, Head of Market Access & External Engagement Germany, UCB
Rob Kettell, Director, Commercial Medicines Negotiation and Complex Transactions, NHS England
Goda Kijauskaite, Senior Consultant, Avalere Health
Elizabeth Kinter, Vice President, Head of Evidence, Value and Access, Vir Biotechnology
Christopher Kipps, Member & Clinical Director, NHS Research SDE Network & UHS R&D
Sandeep Kiri, Global Head, Health Economics and HTA Evidence, Ucb
Lori Klein, Partner, Medical & Scientific Affairs Practice Lead, Putnam
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Hannah Kurth, Founder, PULSEdge
Susanne Laningham, Senior Vice President, Head, Global Access, Pricing & External Engagement, UCB Biopharma Srl
Lydia Lanman, Director, Global Policy, Roche
Marianne Laouri, Executive Director, Value Demonstration, Specialty Products & Quality of Care, Boehringer Ingelheim
Orestis Lazos, Associate Director, Avalere Health
Agathe Le Lay, Vice President, Head of Global Value Evidence & Patient Insights, Medical Affairs, H. Lundbeck A/S
Colombe Le Rudulier, Senior Consultant, Life Sciences, Marbls
Oliver Leatham, Senior Director, Head of RWE, Clarivate
Herve Lilliu, Chief Executive Officer, Inbeeo
Carole Longson, Vice Chair & Honorary Professor of Health Technology Assessment, University of Manchester & Medicines Discovery Catapult
Katja Lundell, Senior Director, Global Head of Pricing, Access and Communications, theramex
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
Richard Macaulay, Senior Vice President, PRECISIONadvisors
Manuela Machado, Head, Global Payer Strategy Solutions, Ucb
Jörg Mahlich, Market Access and Government Affairs Lead, Miltenyi
Charles Makin, Head, RWE and Epi, boehringer ingelheim
Chris Mancill, Senior Vice President, Head, Global Market Access, Pricing, and Value Demonstration, Bristol Myers Squibb
Lorenzo Mantovani, Professor of Public Health, University Of Milano - Bicocca
Andrea Mantovani, VP & Partner, Consulting (Value, Access & Pricing), Alira Health
Anne Marciniak, Market Access and Health Economics Executive, Adelphi Values
Silvy Mardiguian, Senior Director, Head of HEOR, Europe & New Markets, BeiGene
Cécile Matthews, Vice President, Life Sciences, CRA, Charles River Associates
Jake McDowell, Vice President, Head of Market Access and Pricing, Partner Therapeutics
Vivian Mendonca, Senior Vice President, Global Head - Value, Evidence and External Affairs, MENARINI GROUP
Erin Mistry, Executive Vice President, Chief Commercial Officer, CorMedix Inc
Leyla Mohseninejad, Director, BeiGene
Lawrence Monoson, CEO, RxData, Inc.
Lorenzo Montrasio, Independent Expert, Italian Minister of Family, Birth and Equal Opportunities, Former Council of Europe
Paolo Morgese, Head of Public Affairs, Europe, Alliance for Regenerative Medicine
Sam Morrison, Executive Director, Partners4Access
Christine Mossa, Vice President, Global Value & Access, Neuroscience, Ipsen Biopharmaceuticals Canada Inc.
Michael Mueller, Head Of Market Access, Western Europe, Sun Pharma
Neil Mulcock, Vice President, International Government Affairs and Policy, Gilead Sciences
Andrew Mumford, Chief Executive Officer, Initiate Consultancy
Bogdan Muresan, Director, Global HEOR, Astellas Pharma
Noemi Muszbek, Partner and Health Economics Director, Visible Analytics Ltd.
Katrin Nather, Associate Director, Genesis Research Group
Alexander Natz, Director General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Emilie Neez, Director, Dolon
Claudia Neuber, Head of Global Pricing, Oncology, AstraZeneca
Eric Noehrenberg, Global Vice President, Market Access and Government Affairs, CORCYM
Esther Nzenza, Chief Executive Officer & Founder, DECISIVE CONSULTING LTD
Andrew Olaye, Executive Director, Head of Market Access and Partnership EMEA, Orchard Therapeutics Ltd
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Melvin Olson, Founder, Olson Strategies, Olson Strategies GmbH
Donal O'Sullivan, Global Head, Market Access, Mundipharma
Loubna Ouriaghli, Head of Government Affairs and Policy, IPSEN
Gavin Outteridge, Managing Director, AESARA Europe
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Casper Paardekooper, Partner, Vintura, Part of Cencora
Robert Palmer, Head of Market Access, Oncology, boehringer ingelheim
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Lucia Paone, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Bhavesh Patel, Principal, Life Sciences, CRA, Charles River Associates
Preeti Patel, CEO & Founder, Global Pricing Innovations (GPI)
Dilip Patel, VP Market Access, Autolus
Julien Patris, Head of Patient Advocacy and Public Policy, EMEA, arGEN-X
Jonathan Pearson-Stuttard, Head & Chair, LCP Health Analytics & Royal Society for Public Health
Marco Penske, Head, Market Access & Healthcare Affairs, Germany, Boehringer-Ingelheim
Diogo Teixeira Pereira, Affiliate Member of NOVA SBE, Health Economics & Management Knowledge Center, Universidade NOVA de Lisboa
Tomaso Piaggio, Director, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Andres Pichon Riviere, Executive Director, Health Technology Assessment And Economic Evaluations, I.E.C.S.
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Oresta Piniazhko, Director of HTA department, State Expert Centre of MoH
Carme Pinyol, Early Products and HEOR Lead, Novartis
Lara Pippo, Head Of Market Access & Government Affairs, Italy, CSL Behring
Jep Poirrier, Executive Director, Health Economics, Parexel Access Consulting
Luca Luigi Polastri, Global Director, Payor Value and Patient Access Head, Kyowa Kirin
Marie-Monique Poujol de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Julie Powell, Director, Patient Advocacy and Public Affairs, Pleco Therapeutics
Rasmus Prior Gjesing, Head of Global Market Access Policy, Novo Nordisk A/S
Jennifer Quinn, Head of Global Value and Access, Debiopharm International
Andreas Reimann, Co-Founder and Managing Partner, admedicum
Rogerio Ribeiro, Senior Vice President, Head of Global Commercial, Vaccines Business Unit, Takeda
Andre Roeder, Head, Commercial Operations EU, TETEC AG
Stefano Romanelli, Senior Government Affairs Manager, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Ivanna Rosendal, Senior Director, Head of Commercial and Medical IT, Ascendis Pharma A/S
Mihai Rotaru, Director, Market Access, EFPIA
Shaun Rowark, Associate Director, Data Access and Analysis, NICE
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Claus Runge, Senior Vice President, Global Head of Market Access, Public Affairs & Sustainability, Bayer
Jose Luis Sanchez Chorro, Director, Market Access, Spain and Portugal, Jazz Pharmaceuticals
Michael Schlander, Head of Division of Health Economics & Professor of Health Economics, German Cancer Research Center & University of Heidelberg
Fabian Schmidt, Global Head of Market Access, HEOR and Policy, Recordati Rare Diseases
Mette Schrøder Hemels, Vice President, Global Payer Evidence, Novo Nordisk A/S
Philip Schwab, Senior Director, Government Affairs, Europe, AbbVie
Richard Sear, Business Unit Director, Dolon
Ayman Semaan, Market Access & Pricing Lead, Biologix
Shuvayu Sen, Vice President, CORE Oncology, Merck
Hans Severens, Independent HTA Expert, Severens HTA consultancy
Sandip Shah, CEO / President, Market Access Solutions Llc
Kun Shi-van Wielink, EMEA Associate Director, HEOR/RWE Market Access, Santen
Simon Shohet, Vice President, Market Access, International, Amicus Therapeutics
Diana Sinkevich, Head of Access, EU & International, Global Rare Diseases, Chiesi
Paul Slobbe, Director, Access and External Affairs, Takeda Nederland B.V.
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Igor Solev, Global Head of Market Access, Policy & External Payer Affairs, Abbott Laboratories
Seema Sondhi, Head, Payer Value & Access, Takeda
Rafael Souza, Director, Access Solutions & Pricing, New Markets, BeiGene
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Natalie Steck, Director HTA & Access strategy, MSD Sharp & Dohme
Kati Sternberg, Senior Manager Statistics; Team Lead HTA Statistics, AbbVie
Lotte Steuten, Deputy CEO, Office of Health Economics
Gerdi Strydom, Managing Director, Valid Insight
Rachel Studer, Global Executive Director Launch Evidence, Novartis
Meni Styliadou, Vice President, Health Data Partnerships, Data Science Institute, Takeda Pharmaceuticals International AG
Annie Syntosi, Global Associate Director, Value & Access, HEOR, Global Health,, Novartis Pharma AG
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Janssen
Tina Taube, Director, Market Access and Orphan Drug Policy Lead, EFPIA
Sheena Thakkar, Director, Value & Evidence, Pfizer
Jörg Tomeczkowski, Director, HTA Strategy, Institute for evidence-based Positioning in Healthcare
Ariella Toren, Director, Medicine and Medical Technologies, HMOS Department, Ministry of Health, Israel
Ilona Torontali, Global Head, Pricing and Reimbursement, Roche
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Kaan Tunceli, Vice President and Head, Global Value and Real World Evidence, Otsuka Pharmaceutical
Aodan Tynan, Vice President, Global Market Access, Astellas
Allister Upton, Independent Market Access Expert
Bart Van Den Daele, Director, Market Access, Head of External Affairs, Gilead Sciences
Goedele van Haasteren, Deputy chief Section HTA, Federal Office of Public Health, Switzerland
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mary Lynne van Poelgeest-Pomfret, President, World Federation for Incontinence and Pelvic Problems (WFIPP)
Christina Vandorou, Director, Macroeconomics And Health Policy, EMEA, Johnson & Johnson
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Fernando Ventureira, Chief Executive Officer, Stratence Partners
Juliette Vila Sinclair/Spence, Rare Disease Patient Advocate & Chairwoman, Acanthamoeba Keratitis Eye Foundation
Olivier Vogt, Manager, Tenders and Pricing, Bavarian Nordic
Reg Waldeck, Vice President, Oncology Market Access Strategy Leader, Bayer
Mel Walker, Life Sciences Strategic Advisor and Managing Director, BioPharma Futures
Anne Willemsen, Co-chair JCA Subgroup, Zorginstituut Nederland
Lara Wolfson, AVP & Head, HTA Statistics, MSD
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Claire Woon, Agency lead, AMICULUM Access
Lori Yin, Associate Director, Access Lead, Roche
Zinajda Zolic-Karlsson, Senior advisor HTA, Norwegian Medicines Agency
Get Involved
Sponsorship & Exhibition Sales
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
Conference Production
George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940
Marketing Opportunities
Karen Duncan
karen.duncan@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events